The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid
- Author:
Jae Young LEE
1
;
Yasunori MINAMI
;
Byung Ihn CHOI
;
Won Jae LEE
;
Yi-Hong CHOU
;
Woo Kyoung JEONG
;
Mi-Suk PARK
;
Nobuki KUDO
;
Min Woo LEE
;
Ken KAMATA
;
Hiroko IIJIMA
;
So Yeon KIM
;
Kazushi NUMATA
;
Katsutoshi SUGIMOTO
;
Hitoshi MARUYAMA
;
Yasukiyo SUMINO
;
Chikara OGAWA
;
Masayuki KITANO
;
Ijin JOO
;
Junichi ARITA
;
Ja-Der LIANG
;
Hsi-Ming LIN
;
Christian NOLSOE
;
Odd Helge GILJA
;
Masatoshi KUDO
Author Information
- Publication Type:15
- From: Ultrasonography 2020;39(3):191-220
- CountryRepublic of Korea
- Abstract: The first edition of the guidelines for the use of ultrasound contrast agents was published in 2004, dealing with liver applications. The second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some nonliver applications. The third edition of the contrast-enhanced ultrasound (CEUS) guidelines was the joint World Federation for Ultrasound in Medicine and Biology-European Federation of Societies for Ultrasound in Medicine and Biology (WFUMB-EFSUMB) venture in conjunction with other regional US societies such as Asian Federation of Societies for Ultrasound in Medicine and Biology, resulting in a simultaneous duplicate on liver CEUS in the official journals of both WFUMB and EFSUMB in 2013. However, no guidelines were described mainly for Sonazoid due to limited clinical experience only in Japan and Korea. The new proposed consensus statements and recommendations provide general advice on the use of Sonazoid and are intended to create standard protocols for the use and administration of Sonazoid in hepatic and pancreatobiliary applications in Asian patients and to improve patient management.
